© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
<<<